epidemiologyЭпидемиология и ВакцинопрофилактикаEpidemiology and Vaccinal Prevention2073-30462619-0494«Numicom» LLC10.31631/2073-3046-2016-15-4-53-58epidemiology-181Research ArticleИНФОРМАЦИЯ ВОЗWHO INFORMATIONПрименение препаратов Имунофан, Полиоксидоний, Ронколейкин, Сальмозан и Фоспренил для потенцирования гуморального иммунного ответа у кроликов - продуцентов энтеровирусных диагностических сыворотокApplication of Imunofan, Polioksidoniy, Ronkoleykin, Salmozan and Fosprenil for Stimulating the Humoral Immune Response in Rabbits Immunized against EnterovirusesКозловВ. Г.KozlovV. G.vgkozlov@mail.ruХапчаевЮ. Х.KhapchaevYu. Kh.noemail@neicon.ruИшмухаметовА. А.IshmukhametovA. A.noemail@neicon.ruФГУП «Предприятие по производству бактерийных и вирусных препаратов Института полиомиелита и вирусных энцефалитов им. М.П. Чумакова»Russian Federation2016200820161545358Copyright © Козлов В.Г., Хапчаев Ю.Х., Ишмухаметов А.А., 20162016Козлов В.Г., Хапчаев Ю.Х., Ишмухаметов А.А.Kozlov V.G., Khapchaev Y.K., Ishmukhametov A.A.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.epidemvac.ru/jour/article/view/181

Экспериментально определена избирательная и непостоянная адъювантная активность препаратов Иммунофан, Полиоксидоний, Ронколейкин, Сальмозан и Фоспренил, примененных в качестве дополнительных стимуляторов иммунного ответа у кроликов - продуцентов поликлональных энтеровирусных диагностических сывороток для реакции нейтрализации.

Enterprise of viral and bacterial Preparations of Chumakov Institute of poliomyelitis and viral encephalitides, Moscow Abstract Selective and inconstant adjuvant activities of the agents Imunofan, Polioksidoniy, Roncoleykin, Salmozan and Fosprenil were determined. Those agents were used as an additional stimulant of the immune response in rabbit immunized with enteroviruses to get the polyclonal diagnostic sera for neutralization.

кроличьи энтеровирусные нейтрализующие сывороткиадъювантытехнология изготовления сыворотокenterovirus-neunralizing rabbit seraadjuvantssera production technologyReferencesGrandien M., Forsgren M., Ehrnst A. Enteroviruses. In: Diagnostic procedures for viral, rickettsial, and chlamydial infections. Eds.: Lennette E.H., Lennette D.A., Lennette E.T. Wachington, DC: American Public Health Assotiation. 1995: 279 - 297.Grandien M., Forsgren M., Ehrnst A. Enteroviruses. In: Diagnostic procedures for viral, rickettsial, and chlamydial infections. Eds.: Lennette E.H., Lennette D.A., Lennette E.T. Wachington, DC: American Public Health Assotiation. 1995: 279 – 297.Kiang D., Newbower E.C, Yeh E., Wold L., Chen L., Schnurr D. An algoritm for the typing of enteroviruses and correlation to serotyping by viral neutralization. J. Clin. Virol. 2009; 45: 334 - 340.Kiang D., Newbower E.C, Yeh E., Wold L., Chen L., Schnurr D. An algoritm for the typing of enteroviruses and correlation to serotyping by viral neutralization. J. Clin. Virol. 2009; 45: 334 – 340.Khetsuriani N., Parashar U.D. Enteric viral infections: the clinician's guide to diagnosis, treatment and prevention. In: Scentific American Medicine. Eds.: Dale D.C., Federman D.D.N.-Y; 2003: 1758 - 1766.Khetsuriani N., Parashar U.D. Enteric viral infections: the clinician’s guide to diagnosis, treatment and prevention. In: Scentific American Medicine. Eds.: Dale D.C., Federman D.D..N.-Y.; 2003: 1758 – 1766.Palacios G., Oberste M.S. Enterovirus as agents of emerging infectious diseases. J. Neurol. 2005, 11: 424 - 433.Palacios G., Oberste M.S. Enterovirus as agents of emerging infectious diseases. J. Neurol. 2005, 11: 424 – 433.Морозова Н.С., Чернявская О.П., Ясинский А.А., Воронцова Т.В. Эпидемиологический надзор за энтеровирусной (неполио) инфекцией в Российской Федерации. Медицинская вирусология. 2009; Том XXVI: 39 - 41.Morozova N.S., Chernyavskaya O.P., Yasinskyi A.A., Voronzova T.V. Epidemiological surveillance of enterovirus (non-polio) infection in the Russian Federation. Medicinskaya Virusologiya. [Medical Virology]. Chumakov Institute of Poliomyelitis and Viral Encephalitides. 2009; 26: 39 – 41 (in Russian).Лебедева Л.А., Резник В.И., Реброва О.И., Cавосина Л.В., Пристяжнюк Е.Н., Амяга Е.Н. Лабораторное обеспечение эпидемиологического надзора за энтеровирусной инфекцией на востоке России в 2014 году. Медицинская вирусология. 2015; Том XXIX (2): 105 - 106.Lebedeva L.A., Reznik V.I., Rebrova O.I. Savosina L.V., Prysyazhnyuk E.N., Amyaga E.N. Laboratory-based surveillance of enterovirus infection in Eastern Russia in the year 2014. Medicinskaya Virusologiya. [Medical Virology]. Chumakov Institute of Poliomyelitis and Viral Encephalitides. 2015; 29 (2): 105 – 106 (in Russian).Новикова Н.А., Голицина Л.Н., Зверев В.В., Епифанова Н.В., Кашников А.Ю., Сашина Е.А. и др. Молекулярный мониторинг циркуляции неполиомиелитных энтеровирусов на территории России (2008-2015 гг.). Медицинская вирусология. 2015; Том XXIX (2):110.Novikova N.A., Golizina L.N., Zverev V.V., Еpifanova N.V., Kashnikov A.Y., Sashina T.A. et al. Molecular monitoring of non-polio enterovirus circulation in Russia (2008 – 2015). Medicinskaya Virusologiya. [Medical Virology]. Chumakov Institute of Poliomyelitis and Viral Encephalitides. 2015;. 29 (2): 110 (in Russian).Козлов В.Г. Научно-методические и экспериментальные основы усовершенствования производства энтеровирусных диагностических сывороток. Медицинская вирусология. 2009; Том XXVI: 31 - 33.Kozlov V.G. Scientific methodological and experimental approach of production improvement of diagnostic enterovirus sera. Medicinskaya Virusologiya. [Medical Virology]. Chumakov Institute of Poliomyelitis and Viral Encephalitides. 2009; 26: 31 – 33 (in Russian).Козлов В.Г. Поликлональные энтеровирусные диагностические сыворотки нового поколения. Эпидемиология и инфекционные болезни. 2014; 3: 51 - 56.Kozlov V.G. New generation of polyclonal enteroviral diagnostic sera. Epidemiologiya i infekcionnije bolezni. [Epidemiology and infectious diseases]. 2014; 3: 51 – 56 (in Russian).Имунофан. www.rlsnet.ruImunofan. www.rlsnet.ru (in Russian).Полиоксидоний. www.rlsnet.ruPolioxidonium. www.rlsnet.ru (in Russian).Ронколейкин. www.vetLek.ruRoncoleukinum. www.vetLek.ru (in Russian).Сальмозан. www.webvet.ruSalmosanum. www.webvet.ru (in Russian).Фоспренил. www.fosprenil.ruFosprenil. www.fosprenil.ru (in Russian).Polio Laboratory Manual, 2004, 4th edition Geneva: Department of Vaccines and Biologicals, World Health Organization; 2004.Polio Laboratory Manual, 2004, 4th edition Geneva: Department of Vaccines and Biologicals, World Health Organization; 2004.National Foundation for Infantile Paralysis. Preparation and use of ECHO virus rabbit antisera for types 1 to 14 and Coxsackie virus antisera for types B1 to B5 and A9, prepared by Microbiological Associations Inc. 1957.National Foundation for Infantile Paralysis. Preparation and use of ECHO virus rabbit antisera for types 1 to 14 and Coxsackie virus antisera for types B1 to B5 and A9, prepared by Microbiological Associations Inc. 1957.Odean M.J., Van Frane C.M., der Vieren M., Tomai. M.A., Johnson A.G. Involvement of gamma interferon in antibody enhancement by adjuvants. Infect. Immun. 1990; 58: 427 - 432.Odean M.J., Van Frane C.M., der Vieren M., Tomai. M.A., Johnson A.G. Involvement of gamma interferon in antibody enhancement by adjuvants. Infect. Immun. 1990; 58: 427 – 432.Bliss J., Maylor R., Stokes K., Murrey K.S., Ketchum M.A., Wolf S.F. 8 Interleukin-12 as vaccine adjuvant. Characteristics of primary, recall, and ling- term responses. Ann. NY Acad. Sci. 1996; 795: 26 - 35.Bliss J., Maylor R., Stokes K., Murrey K.S., Ketchum M.A., Wolf S.F. 8 Interleukin-12 as vaccine adjuvant. Characteristics of primary, recall, and ling- term responses. Ann. NY Acad. Sci. 1996; 795: 26 – 35.Nunberg J.H., Doyle M.V., York S.M., York C.J. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc. Natl Acad. Sci. USA. 1989; 86: 4240 - 4243.Nunberg J.H., Doyle M.V., York S.M., York C.J. Interleukin 2 acts as an adjuvant to increase the potency of inactivated rabies virus vaccine. Proc. Natl Acad. Sci. USA. 1989; 86: 4240 – 4243.Pardoll D.M. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 1995; 13: 399 - 415.Pardoll D.M. Paracrine cytokine adjivants in cancer immunotherapy. Annu. Rev. Immunol. 1995; 13: 399 – 415.Jennings V.M. Review of selected adjuvants used in antibody production. ILAR J. 1995; 37 (3): 119 - 125.Jennings V.M. Review of selected adjuvants used in antibody production. ILAR J. 1995; 37 (3): 119 – 125.Stills H.F. Adjuvants and antibody production: dispelling the myths associated with Freund’s Complete and other adjuvants. ILAR J. 2005, 46, N.3:280 - 293.Stills H.F. Adjuvants and antibody production: dispelling the myths associated with Freund’s Complete and other adjuvants. ILAR J. 2005, 46, N.3:280 – 293.Kawai T., Akira S. TLR signaling. Semin. Immunol. 2007; 19: 24 - 32.Kawai T., Akira S. TLR signaling. Semin. Immunol. 2007; 19: 24 – 32.

The authors declare that there are no conflicts of interest present.